Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

Sebastiano Bruno Solerte1 · Antonio Di Sabatino2 · Massimo Galli3,4 · Paolo Fiorina5,6,7

Abstract
Aims SARS–CoV-2 causes severe respiratory syndrome (COVID-19) with high mortality due to a direct cytotoxic viral effect and a severe systemic inflammation. We are herein discussing a possible novel therapeutic tool for COVID-19.

Methods Virus binds to the cell surface receptor ACE2; indeed, recent evidences suggested that SARS–CoV-2 may be using as co-receptor, when entering the cells, the same one used by MERS–Co-V, namely the DPP4/CD26 receptor. The aforementioned observation underlined that mechanism of cell entry is supposedly similar among different coronavirus, that the co-expression of ACE2 and DPP4/CD26 could identify those cells targeted by different human coronaviruses and that clinical complications may be similar.

Results The DPP4 family/system was implicated in various physiological processes and diseases of the immune system, and DPP4/CD26 is variously expressed on epithelia and endothelia of the systemic vasculature, lung, kidney, small intestine and heart. In particular, DPP4 distribution in the human respiratory tract may facilitate the entrance of the virus into the airway tract itself and could contribute to the development of cytokine storm and immunopathology in causing fatal COVID-19 pneumonia.

Conclusions The use of DPP4 inhibitors, such as gliptins, in patients with COVID-19 with, or even without, type 2 diabetes, may offer a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.

Keywords DPP4 inhibitors · Pneumonia · Diabetes · SARS–CoV-2 · Cytokine storm

Introduction
The novel beta-coronavirus 2019 (SARS–CoV-2) has recently emerged as a threat for human kind, causing severe respiratory syndrome (COVID-19), associated with other systemic complications (i.e., intestinal infections, renal and heart failure) and with a relative high mortality [1]. This pathology has emerged from Wuhan City, in the China region of Hubei, and then spreading in Europe, Asia and USA [1]. This new pandemia follows the severe acute coronavirus respiratory syndrome of 2002–2003 (SARS–CoV), observed in the Guangdong Province of China and the Middle East respiratory syndrome coronavirus of 2012 (MERS–Co-V), mainly affecting the Arabian peninsula [1].

Coronaviruses tropism is primarily determined by the ability of the spike (S) entry glycoprotein to bind to a cell surface receptor. It is well reported now that SARS–CoV-2 may use angiotensin-converting enzyme 2 (ACE2), the same receptor of SARS–CoV, to infect humans [2]. However, recent evidences demonstrated that SARS–CoV-2 binds to
DPP4/CD26 when entering into cells of the respiratory tract [3]. It appears that the interaction between SARS–CoV-2 spike glycoprotein and the human DPP4/CD26, also known as dipeptidyl peptidase-4 (DPP4), is a key factor for the hijacking and virulence [3]. Interestingly, another recent study clearly reported a correlation between DPP4 and ACE2, suggesting that both membrane proteins are relevant in the pathogenesis of virus entry [4]. The co-expression of ACE2 and DPP4/CD26 as receptors of spike glycoproteins could hypothesize that different human coronaviruses (CoVs) target similar cell types across different human tissues and explain the presence of similar clinical features in patients infected with different CoVs. In another case, it was shown that DPP4 acted for CoV co-receptor, thus suggesting a potential similar mechanism of entry for SARS–CoV-2 [5].

Dipeptidyl peptidase-4 (DPP4), also known as CD26, is a widely expressed serine membrane-anchored ectopeptidase that exists on the surface of different cell types and cleaves dipeptides from the N-terminus, where a proline residue is in a penultimate position [6]. Besides its catalytic activity, DPP4 also acts as a binding protein and a ligand of extracellular factors and a large number of molecules can be cleaved by DPP4. This peptidase transmits intracellular signals through a small intracellular tail that cleave proline and more rapidly alanine and glycine [7, 8]. In particular, post-translational N-terminal hypersialylation may be implicated in DPP4 trafficking and virus aggressivity [9, 10] and, as already demonstrated in MERS–CoV and porcine respiratory coronavirus, could involve the N-glycan binding interfaces of DPP4 [11].

Clinical and experimental research over the past 30 years has clearly suggested that the DPP4/CD26 pathway is involved in various physiological processes and diseases of the immune system [12]; not surprising for a molecule as CD26 that was originally described as a surface marker of T lymphocytes [13]. DPP4/CD26 transmembrane glycoprotein is not only expressed by various cells of the immune system, but also by epithelial and endothelial cells of systemic vasculature, by the endothelial cells of venules and capillaries, by the kidney, small intestine, lung, pancreas, spleen and heart, by the vascular smooth muscle cells, and by monocytes and hepatocytes and is soluble in the plasma [6, 7, 14]. In rats, lung appeared to be organ with the second highest expression of DPP4/CD26 [15]; in particular, lung parenchyma, interstitium and pleural mesothelia were shown to be relative rich in DPP4 protein and are the lung area most affected by the CoVs-related injuries [16, 17]. The relation between DPP4/CD26 expression and site of CoVs-related injuries is overall well demonstrated in MERS–Co-V infection, where DPP4 could directly influence the kinetic of lung inflammation and may act itself as a proinflammatory signaling molecule [16, 18]. In COVID-19, although lacking of extensive pathological data, it appeared to be confirmed the aforementioned dynamic of correlation between DPP4/CD26 localization and site of lung inflammation [3]. Interestingly, both MERS–Co-V and SARS–CoV-2 predominantly infect lower airways and may cause acute respiratory distress syndrome (ARDS) and irreversible fatal pneumonia [17, 19, 20]. Furthermore, both SARS–CoV and MERS–Co-V are characterized by an important cytokine storm, with a similar immunopathology [21]. Virus infection and replication cause delayed interferon response, severe inflammatory monocyte macrophage and neutrophil infiltration and uncontroled flood of proinflammatory cytokines and chemokines [22]. Moreover, there are evidences of diffuse vascular leakage, endothelial and epithelial apoptosis and of a diffuse microangiopathy with ischemic and thrombotic lesions that induce alveolar edema and collapse [22]. This may be a dramatic link between COVID-19 and diabetes, because the latter are more susceptible to abnormal coagulation and fibrinolysis, to impaired tissue remodeling and to multiorgan fibrosis and failure [23–27]. Taken together, all these findings clearly indicated that the aggressive impact of CoVs (SARS–CoV, MERS–Co-V and COVID-19) on tissues and organs is preferentially modulated, or least co-modulated, by DPP4/CD26 [28] and that DPP4/CD26 inhibition could antagonize this mechanism. DPP4/CD26 system modulation may be one of the new approaches to be employed for the pharmacologic treatment of COVID-19. The large amount of data available on the use of DPP4 inhibitors could support us to give a new strategic direction in COVID-19 treatment [6, 12, 29–33]. The pharmacological possibility to inhibit DPP4/CD26 activity by using commercial DPP4 inhibitors or gliptins (e.g., sitagliptin, linagliptin, vildagliptin and others) may represent a valid weapon to block the host CD26 receptor, thus disabling SARS–CoV-2 way to enter T cells [3, 34]. Along this line of investigation, we recently started at Sacco Hospital in Milan and at San Matteo Hospital in Pavia, the clinical trial SIDIACO (sitagliptin in diabetic patients with COVID-19). SIDIACO is a case–control study, in which we will compare the clinical response of diabetic patients infected by COVID-19 during a 10 days course treatment with 100 mg Sitagliptin.

Several data suggested that the latter immune pharmacological activity of DPP4 seems to be independent of its catalytic activity [35] and for this reason unaffected by the use of inhibitors of the enzymatic activity of DPP4 [36]. Other scientific evidences supported that the use of DPP4/CD26 inhibitors may act to antagonize airway inflammation [37]. DPP4 inhibition by gliptins may antagonize SARS–Co-V virulence and multiorgan acute and chronic damage by means of several additive mechanisms that involve: (1) reduction of cytokines overproduction [12, 30, 38, 39]; (2) downregulation of macrophages activity/function [40]; (3) enhancement of GLP-1 anti-inflammatory activity [41, 42], particularly in those aged patients.
with COVID-19 [43]; (4) stimulation of direct pulmonary anti-inflammatory effects [44, 45].

In summary, we hypothesize (Fig. 1) that DPP4/CD26 inhibition with gliptins, and particularly with those with more highly selectivity for DPP4 [46, 47], could represent a new strategy to support the treatment of COVID-19 in patients with or without diabetes.

Acknowledgements We thank the Fondazione Romeo and Enrica Invernizzi for the extraordinary support.

Author contributions SBS, ADS, MG and PF designed and wrote the paper. All authors were given full access to all data presented in this study and are responsible for the integrity of the data and accuracy of the data analysis. All authors have given their permission for submission of this manuscript.

Funding Paolo Fiorina is supported by an Italian Ministry of Health Grant RF-2016-02362512 and by Linea-2 2019 funding from Università di Milano. Paolo Fiorina is supported by Fondazione Romeo and Enrica Invernizzi.

Availability of data and material All data generated or analyzed during this study are available from the corresponding author on reasonable request.

Code availability Not applicable.

Compliance with ethical standards

Conflict of interest The authors declare no present or potential conflicts of interest. This study was performed without the support or involvement of any external funding source or study sponsor in any phase of the investigation, or in the writing or submission of the manuscript.
Consent to participate N/A.

Consent to publish The participants provided informed consent for publication.

Human and animal rights disclosure N/A.

References

1. Guan WJ et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. https://doi.org/10.1056/NEJMoa2002032
2. Zhou P et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273
3. Vankadari N, Wilce JA (2020) Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect 9(1):601–604
4. Qi F et al (2020) Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun 526(1):135–140. https://doi.org/10.1016/j.bbrc.2020.03.044
5. Raj VS et al (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495(7440):251–254
6. Lambeir AM et al (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40(3):209–294
7. Lei Y et al (2017) Dipeptidyl peptidase-IV inhibition for the treatment of cardiovascular disease- recent insights focusing on angiogenesis and neovascularization. Cire J 81(6):770–776
8. Nistala R, Savin V (2017) Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. Am J Physiol Renal Physiol 312(4):F661–F670
9. Slimane TA et al (2000) Apical secretion and sialylation of soluble dipeptidyl peptidase IV are two related events. Exp Cell Res 258(1):184–194
10. Cuchacovich M et al (2001) Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol 19(6):673–680
11. Lu G et al (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500(7461):227–231
12. Waumans Y et al (2015) The dipeptidyl peptidase family. prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front Immunol 6:387
13. Schon E et al (1984) Dipeptidyl peptidase IV of human lymphocytes. Evidence for specific hydrolysis of glycy1prol1-p-nitroanilide in T-lymphocytes. Biochem J 223(1):255–258
14. Durinx C et al (2000) Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 267(17):5608–5613
15. Schade J et al (2008) Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem 56(2):147–155
16. Meyerholz DK, Lambertz AM, McCray PB Jr (2016) Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the middle east respiratory syndrome. Am J Pathol 186(1):78–86
17. Zaki AM et al (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814–1820
18. Wronkowitz N et al (2014) Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim Biophys Acta 1842(9):1613–1621
19. Drosten C et al (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348(20):1967–1976
20. Kuiken T et al (2003) Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362(9380):263–270
21. Channappanavar R, Perlman S (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39(5):529–539
22. Channappanavar R et al (2016) Dysregulated Type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19(2):181–193
23. Guo YR et al (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil Med Res 7(1):11
24. Loretti C et al (2020) Embryonic stem cell extracts improve wound healing in diabetic mice. Acta Diabetol. https://doi.org/10.1007/s00592-020-01500-0
25. Fiorina P et al (2004) Normalization of multiple hemostatic abnormalities in uremic type 1 diabetic patients after kidney-pancreas transplantation. Diabetes 53(9):2291–2300
26. D’ Addio F et al (2015) Circulating IGF-I and IGFBP3 levels control human colonic stem cell function and are disrupted in diabetic enteropathy. Cell Stem Cell 17(4):486–498
27. Astorri E et al (1997) Isolated and preclinical impairment of left ventricular filling in insulin-dependent and non-insulin-dependent diabetic patients. Clin Cardiol 20(6):536–540
28. Kleine-Weber H et al (2020) Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. Emerg Microbes Infect 9(1):155–168
29. Hopsu-Havu VK, Glenner GG (1966) A new dipeptide naphthylamide: the substrate for a new enzyme. Biochim Biophys Acta 111:257–263
30. Klemann C et al (2016) Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol 185(1):1–21
31. Trzaskalski NA, Fadzeyeja E, Mulvihill EE (2020) Dipeptidyl peptidase-4 at the interface between inflammation and metabolism. Clin Med Insights: Endocrinol Diabetes 13:1179551420912972
32. Ling J et al (2019) The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetol 56(3):249–272
33. Ling J et al (2019) DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews. Acta Diabetol 56(1):7–27
34. Morimoto C, Schlossman SF (1998) The structure and function of CD26 in the T-cell immune response. Immunol Rev 161:55–70
35. Huhn J et al (2000) Molecular analysis of CD26-mediated signal transduction in T cells. Immunol Lett 72(2):127–132
36. Vora KA et al (2009) Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol 10:19
37. Kruischinski C et al (2005) CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model. Clin Exp Immunol 139(1):17–24
38. Ikeda T et al (2013) Soluble CD26/dipeptidyl peptidase IV enhances the transcription of IL-6 and TNF-alpha in THP-1 cells and monocytes. PLoS ONE 8(6):e66520
39. Pedersen SF, Ho YC (2020) SARS-CoV-2: a storm is raging. J Clin Invest. https://doi.org/10.1172/JCI137647
40. Al-Qahtani AA et al (2017) Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARgamma. Oncotarget 8(6):9053–9066
41. Lee YS et al (2012) Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 55(9):2456–2468
42. Lee YS, Jun HS (2016) Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. https://doi.org/10.1155/2016/3094642
43. Cheng XW et al (2018) Dose rectification of an imbalance between DPP4 and GLP-1 ameliorates chronic stress-related vascular aging and atherosclerosis? Clin Exp Pharmacol Physiol 45(5):467–470
44. Kawasaki T et al (2018) DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 315(5):L834–L845
45. Xu J et al (2018) Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension. Lab Invest 98(10):1333–1346
46. Deacon CF, Lebovitz HE (2016) Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab 18(4):333–347
47. Deacon CF (2019) Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of Type 2 diabetes. Front Endocrinol (Lausanne) 10:80

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.